BR112023017099A2 - Anticorpos que se ligam a cd123 e a receptores de células t gama-delta - Google Patents

Anticorpos que se ligam a cd123 e a receptores de células t gama-delta

Info

Publication number
BR112023017099A2
BR112023017099A2 BR112023017099A BR112023017099A BR112023017099A2 BR 112023017099 A2 BR112023017099 A2 BR 112023017099A2 BR 112023017099 A BR112023017099 A BR 112023017099A BR 112023017099 A BR112023017099 A BR 112023017099A BR 112023017099 A2 BR112023017099 A2 BR 112023017099A2
Authority
BR
Brazil
Prior art keywords
antibodies
bind
delta
gamma
cell receptors
Prior art date
Application number
BR112023017099A
Other languages
English (en)
Inventor
Merette Mousset Charlotte
Lutje Hulsik David
Jelle Van Der Vliet Johannes
Matthijs Ruben Jurjen
Willem Henri Ida Parren Paul
Cornelis Roovers Robertus
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of BR112023017099A2 publication Critical patent/BR112023017099A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos que se ligam a cd123 e a receptores de células t gama-delta. a presente invenção refere-se a anticorpos que têm capacidade de ligação a cd123 humano e que têm capacidade de ligação à cadeia vd2 de um receptor de células t de v?9vd2 humana. a invenção refere-se ainda a composições farmacêuticas que compreendem os anticorpos da invenção e a usos dos anticorpos da presente invenção para tratamento médico.
BR112023017099A 2021-02-26 2022-02-28 Anticorpos que se ligam a cd123 e a receptores de células t gama-delta BR112023017099A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US202163274709P 2021-11-02 2021-11-02
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (1)

Publication Number Publication Date
BR112023017099A2 true BR112023017099A2 (pt) 2023-11-21

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017099A BR112023017099A2 (pt) 2021-02-26 2022-02-28 Anticorpos que se ligam a cd123 e a receptores de células t gama-delta

Country Status (9)

Country Link
US (1) US20240141071A1 (pt)
EP (1) EP4298125A1 (pt)
JP (1) JP2024507937A (pt)
KR (1) KR20230169950A (pt)
AU (1) AU2022225091A1 (pt)
BR (1) BR112023017099A2 (pt)
CA (1) CA3209454A1 (pt)
MX (1) MX2023009950A (pt)
WO (1) WO2022180271A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
WO2014081202A1 (ko) 2012-11-21 2014-05-30 주식회사 파멥신 Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
JP6617138B2 (ja) 2014-04-10 2019-12-11 ラヴァ・セラピューティクス・ベー・フェー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
EP3853256A1 (en) 2018-09-19 2021-07-28 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
CN114040926A (zh) * 2019-05-04 2022-02-11 印希比股份有限公司 结合cd123的多肽及其用途
BR112021022089A2 (pt) 2019-05-08 2022-02-08 Janssen Biotech Inc Materiais e métodos para modulação da imunidade mediada por células t

Also Published As

Publication number Publication date
EP4298125A1 (en) 2024-01-03
AU2022225091A1 (en) 2023-09-07
WO2022180271A1 (en) 2022-09-01
JP2024507937A (ja) 2024-02-21
US20240141071A1 (en) 2024-05-02
MX2023009950A (es) 2023-11-10
KR20230169950A (ko) 2023-12-18
CA3209454A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112018012794A2 (pt) receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr
BR112022021322A2 (pt) Anticorpo contra nectina-4 e aplicação do mesmo
BR112022011749A2 (pt) Anticorpos anti-ccr8 e seus usos
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112021015238A8 (pt) Novos anticorpos de ligação a cd40
BR112023017099A2 (pt) Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
BR112022018088A2 (pt) Novos anticorpos anti-lilrb4 e produtos derivados
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
BR112016020871A2 (pt) anticorpos anti-mcam e métodos associados de uso
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
BR112018002436A2 (pt) tratamento de combinação de usos de métodos destes
AR083937A1 (es) Proteinas de union a antigenos
AR119346A1 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112023019749A2 (pt) Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos
BR112022009510A2 (pt) Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
BR112023000515A2 (pt) Composição farmacêutica e seu uso